B-cell lymphoma of mucosa-associated lymphoid tissue - null regimens

The purpose of this page is to provide references to "null therapy" such as placebo and observation. These references provide further insight into the historical development of the treatment landscape. See the main MALT lymphoma page for regimens that include active anticancer treatment.

Consolidation after first-line therapy

Observation

Regimen

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Hancock et al. 2008 (LY03)	1995-2001	Phase 3 (C)	Chlorambucil	Did not meet primary endpoint of RR

No further treatment.

Preceding treatment

• H. pylori eradication therapy

References

1. LY03: Hancock BW, Qian W, Linch D, Delchier JC, Smith P, Jakupovic I, Burton C, Souhami R, Wotherspoon A, Copie-Bergman C, Capella C, Traulle C, Levy M, Cortelazzo S, Ferreri AJ, Ambrosetti A, Pinotti G, Martinelli G, Vitolo U, Cavalli F, Gisselbrecht C, Zucca E. Chlorambucil versus observation after anti-Helicobacter therapy in gastric MALT lymphomas: results of the international randomised LY03 trial. Br J Haematol. 2009 Feb;144(3):367-75. Epub 2008 Nov 22. link to original article link to PMC article PubMed NCT00003617